These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 25681127)

  • 1. Natural antimicrobial peptides against Mycobacterium tuberculosis.
    Abedinzadeh M; Gaeini M; Sardari S
    J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity.
    Yathursan S; Wiles S; Read H; Sarojini V
    J Pept Sci; 2019 Nov; 25(11):e3213. PubMed ID: 31515916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial peptides as an alternative to anti-tuberculosis drugs.
    AlMatar M; Makky EA; Yakıcı G; Var I; Kayar B; Köksal F
    Pharmacol Res; 2018 Feb; 128():288-305. PubMed ID: 29079429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between antimicrobial peptides and mycobacteria.
    Gutsmann T
    Biochim Biophys Acta; 2016 May; 1858(5):1034-43. PubMed ID: 26851776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro.
    Silva S; Santos-Silva A; da Costa JMC; Vale N
    J Glob Antimicrob Resist; 2019 Dec; 19():132-135. PubMed ID: 31154008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
    Ganihigama DU; Sureram S; Sangher S; Hongmanee P; Aree T; Mahidol C; Ruchirawat S; Kittakoop P
    Eur J Med Chem; 2015 Jan; 89():1-12. PubMed ID: 25462220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico comparison of antimycobacterial natural products with known antituberculosis drugs.
    Espinoza-Moraga M; Njuguna NM; Mugumbate G; Caballero J; Chibale K
    J Chem Inf Model; 2013 Mar; 53(3):649-60. PubMed ID: 23410241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitubercular Marine Natural Products.
    Wang L; Wang J; Liu J; Liu Y
    Curr Med Chem; 2018; 25(20):2304-2328. PubMed ID: 28088903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in antitubercular natural products.
    García A; Bocanegra-García V; Palma-Nicolás JP; Rivera G
    Eur J Med Chem; 2012 Mar; 49():1-23. PubMed ID: 22280816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Peptides: A Promising Strategy for Anti-tuberculosis Therapeutics.
    Ning Y; Wang L; Wang M; Meng X; Qiao J
    Protein Pept Lett; 2023; 30(4):280-294. PubMed ID: 36924097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria.
    Sharma S; Hameed S; Fatima Z
    Recent Pat Biotechnol; 2016; 10(2):167-174. PubMed ID: 27652611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review.
    R PA; Anbarasu A
    Probiotics Antimicrob Proteins; 2023 Dec; 15(6):1539-1566. PubMed ID: 36576687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
    Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
    Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural products as leads for tuberculosis drug development.
    Salomon CE; Schmidt LE
    Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery.
    Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S
    Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.
    Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL
    Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.